PE20070240A1 - 7-aza-indazoles sutituidos, composiciones que los contienen y procedimiento de fabricacion - Google Patents
7-aza-indazoles sutituidos, composiciones que los contienen y procedimiento de fabricacionInfo
- Publication number
- PE20070240A1 PE20070240A1 PE2006000933A PE2006000933A PE20070240A1 PE 20070240 A1 PE20070240 A1 PE 20070240A1 PE 2006000933 A PE2006000933 A PE 2006000933A PE 2006000933 A PE2006000933 A PE 2006000933A PE 20070240 A1 PE20070240 A1 PE 20070240A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- pyridin
- sutituted
- indazoles
- aza
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 AZAINDAZOLE COMPOUND Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
REFERIDA A UN COMPUESTO AZAINDAZOL DE FORMULA (I), DONDE A Y Ar SON ARILO, HETEROARILO, HETEROCICLILO, ENTRE OTROS; L ES NH, NH-SO2, SO2NH, ENTRE OTROS; X ES N O NO; R3 ES H Y NHMR"3; M ES UN ENLACE, CO, CO-NH, CS, CS-NH, SO2; R"3 ES H, ALQUILO, ALQUILENO, ALQUINILO, ENTRE OTROS; R4 ES H, HALOGENO, ALQUILO, ENTRE OTROS; R5 ES H, HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-[4-(3-AMINO-1H-PIRAZOLO[3,4-b]PIRIDIN-6-IL)-FENIL]-3-(2-FLUORO-5-TRIFLUOROMETIL-FENIL)-UREA, (6-{4-[3-(2 FLUORO-5-TRIFLUOROMETIL-FENIL)-UREIDO]-FENIL}-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-AMIDA DEL ACIDO TIOFEN-3-CARBOXILICO, (2-MORFOLIN-4-IL-ETIL)AMIDA DEL ACIDO 6-[2-(3-FENIL-UREIDO)-TIAZOL-5-IL]-1H-PIRAZOLO[3,4-b]PIRIDIN-4-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE LAS PROTEINAS, EN PARTICULAR DE LAS QUINASAS Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ENFERMEDADES INFLAMATORIAS DEL INTESTINO, CANCERES, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508316A FR2889526B1 (fr) | 2005-08-04 | 2005-08-04 | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070240A1 true PE20070240A1 (es) | 2007-04-12 |
Family
ID=36177926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000933A PE20070240A1 (es) | 2005-08-04 | 2006-08-02 | 7-aza-indazoles sutituidos, composiciones que los contienen y procedimiento de fabricacion |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8058290B2 (es) |
| EP (1) | EP1912988B1 (es) |
| JP (1) | JP5128475B2 (es) |
| KR (1) | KR101263970B1 (es) |
| CN (2) | CN102093353B (es) |
| AR (1) | AR057719A1 (es) |
| AU (1) | AU2006277855B2 (es) |
| BR (1) | BRPI0614304A2 (es) |
| CA (1) | CA2617293C (es) |
| CR (1) | CR9678A (es) |
| DO (1) | DOP2006000179A (es) |
| EA (1) | EA019302B1 (es) |
| EC (1) | ECSP088152A (es) |
| FR (1) | FR2889526B1 (es) |
| HN (1) | HN2008000188A (es) |
| IL (1) | IL188792A0 (es) |
| MA (1) | MA29652B1 (es) |
| MX (1) | MX2008001614A (es) |
| MY (1) | MY147488A (es) |
| NI (1) | NI200800020A (es) |
| NO (1) | NO20081013L (es) |
| NZ (1) | NZ565396A (es) |
| PE (1) | PE20070240A1 (es) |
| TN (1) | TNSN08024A1 (es) |
| TW (1) | TWI378930B (es) |
| UA (1) | UA94417C2 (es) |
| UY (1) | UY29727A1 (es) |
| WO (1) | WO2007017577A1 (es) |
| ZA (1) | ZA200800965B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP2001880A2 (en) | 2006-03-07 | 2008-12-17 | Array Biopharma, Inc. | Heterobicyclic pyrazole compounds and methods of use |
| US8931114B2 (en) | 2008-09-22 | 2015-01-13 | The United States Of America, As Represented By The Secretary Of The Navy | Elastomeric composites with tether-containing, conducting polymers for nanoscale diffusion control |
| WO2010033966A1 (en) * | 2008-09-22 | 2010-03-25 | The Government of the United State of America, as represented by the Secretary of the Navy | Tether-containing conducting polymers |
| EP2426135A4 (en) * | 2009-04-27 | 2013-02-20 | Shionogi & Co | UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| US8648086B2 (en) | 2009-08-24 | 2014-02-11 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
| EP2491033A4 (en) * | 2009-10-20 | 2013-03-13 | Eiger Biopharmaceuticals Inc | AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| JP5889875B2 (ja) * | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| DK2614369T3 (en) | 2010-09-10 | 2016-05-02 | Epizyme Inc | METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013039988A1 (en) | 2011-09-13 | 2013-03-21 | Glax0Smithkline Llc | Azaindazoles |
| EP2760862B1 (en) * | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US10138235B2 (en) | 2011-12-14 | 2018-11-27 | Sanofi | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| IL282732B2 (en) | 2012-04-13 | 2023-04-01 | Eisai R&D Man Co Ltd | Salt form of human histone methyltransferase inhibitor 2ezh |
| WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| JP6461803B2 (ja) | 2012-10-15 | 2019-01-30 | エピザイム，インコーポレイティド | 置換ベンゼン化合物 |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| MY185765A (en) | 2014-06-17 | 2021-06-06 | Pfizer | Substituted dihydroisoquinolinone compounds |
| US11059817B2 (en) | 2015-09-23 | 2021-07-13 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| CN107619388A (zh) * | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN107840842A (zh) | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| PE20190657A1 (es) | 2016-09-23 | 2019-05-08 | Novartis Ag | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos |
| EP3551613A4 (en) | 2016-12-07 | 2020-07-22 | New Era Pharma, Inc. | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND THEIR PROCESSES |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| CN111138426B (zh) * | 2018-11-02 | 2023-03-10 | 安徽中科拓苒药物科学研究有限公司 | 吲唑类激酶抑制剂及其用途 |
| CN109456280B (zh) * | 2018-12-24 | 2020-11-10 | 锦州医科大学 | 含有脲结构的4-苯基噻唑-2-胺类衍生物及其制备方法与应用 |
| WO2020178316A1 (en) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | 5- or 7-azaindazoles as beta-lactamase inhibitors |
| KR20220045954A (ko) | 2019-07-11 | 2022-04-13 | 이스케이프 바이오, 인크. | Lrrk2 억제제들로서의 인다졸들 및 아자인다졸들 |
| AU2022301047A1 (en) | 2021-06-28 | 2024-01-04 | Blueprint Medicines Corporation | Cdk2 inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1302287A (es) * | 1970-07-21 | 1973-01-04 | ||
| DE2538950A1 (de) * | 1975-09-02 | 1977-03-03 | Basf Ag | Verfahren zur herstellung von 2,6- dichlor-nicotinsaeuren |
| DE2701610A1 (de) * | 1977-01-17 | 1978-07-20 | Basf Ag | Farbstoffzubereitungen fuer cellulose und cellulosehaltiges textilmaterial und neue farbstoffe |
| DD154538A1 (de) * | 1979-07-30 | 1982-03-31 | Eberhard Schroetter | Verfahren zur herstellung substituierter 2,4-und 2,6-dihalogen-pyridine |
| JPH04117362A (ja) * | 1990-09-07 | 1992-04-17 | Idemitsu Kosan Co Ltd | ピリジン誘導体およびその塩ならびに該物質を有効成分とする殺虫・殺ダニ剤 |
| PT1268481E (pt) * | 1999-09-17 | 2008-03-19 | Abbott Gmbh & Co Kg | Inibidores de quinases como agentes terapêuticos |
| EE05405B1 (et) | 2000-08-10 | 2011-04-15 | Pharmacia Italia S.P.A. | Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| US6977262B2 (en) * | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| FR2827603B1 (fr) * | 2001-07-18 | 2003-10-17 | Oreal | Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques |
| CA2461363A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| WO2004009596A2 (en) | 2002-07-23 | 2004-01-29 | Smithkline Beecham Corporation | Pyrazolopyrimidines as kinase inhibitors |
| JP2006501217A (ja) | 2002-08-12 | 2006-01-12 | スージェン・インコーポレーテッド | 新規キナーゼ阻害剤としての３−ピロリル−ピリドピラゾールおよび３−ピロリル−インダゾール |
| PL378296A1 (pl) | 2003-02-27 | 2006-03-20 | Palau Pharma S.A. | Pochodne pirazolopirydyny |
| US7638530B2 (en) * | 2003-04-24 | 2009-12-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| DE602004032587D1 (de) | 2003-09-16 | 2011-06-16 | Panasonic Corp | Codierungsvorrichtung und Decodierungsvorrichtung |
| KR100703068B1 (ko) * | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| FR2871158A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2006076442A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| PE20061119A1 (es) | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| WO2006099075A2 (en) | 2005-03-10 | 2006-09-21 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| EP1876178B1 (en) | 2005-04-28 | 2015-05-27 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
| EP1963332A1 (en) | 2005-11-09 | 2008-09-03 | Memory Pharmaceuticals Corporation | 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
-
2005
- 2005-08-04 FR FR0508316A patent/FR2889526B1/fr not_active Expired - Fee Related
-
2006
- 2006-08-01 EA EA200800514A patent/EA019302B1/ru not_active IP Right Cessation
- 2006-08-01 AU AU2006277855A patent/AU2006277855B2/en not_active Ceased
- 2006-08-01 UA UAA200802787A patent/UA94417C2/ru unknown
- 2006-08-01 JP JP2008524545A patent/JP5128475B2/ja not_active Expired - Fee Related
- 2006-08-01 MX MX2008001614A patent/MX2008001614A/es active IP Right Grant
- 2006-08-01 CN CN2011100326106A patent/CN102093353B/zh not_active Expired - Fee Related
- 2006-08-01 NZ NZ565396A patent/NZ565396A/en not_active IP Right Cessation
- 2006-08-01 CN CN2006800323586A patent/CN101304998B/zh not_active Expired - Fee Related
- 2006-08-01 BR BRPI0614304-0A patent/BRPI0614304A2/pt not_active IP Right Cessation
- 2006-08-01 CA CA2617293A patent/CA2617293C/fr not_active Expired - Fee Related
- 2006-08-01 EP EP06794254.0A patent/EP1912988B1/fr active Active
- 2006-08-01 ZA ZA200800965A patent/ZA200800965B/xx unknown
- 2006-08-01 WO PCT/FR2006/001861 patent/WO2007017577A1/fr active Application Filing
- 2006-08-02 PE PE2006000933A patent/PE20070240A1/es not_active Application Discontinuation
- 2006-08-02 MY MYPI20063746A patent/MY147488A/en unknown
- 2006-08-02 DO DO2006000179A patent/DOP2006000179A/es unknown
- 2006-08-03 AR ARP060103384A patent/AR057719A1/es not_active Application Discontinuation
- 2006-08-04 UY UY29727A patent/UY29727A1/es not_active Application Discontinuation
- 2006-08-04 TW TW095128577A patent/TWI378930B/zh not_active IP Right Cessation
-
2008
- 2008-01-15 IL IL188792A patent/IL188792A0/en unknown
- 2008-01-18 TN TNP2008000024A patent/TNSN08024A1/en unknown
- 2008-01-18 NI NI200800020A patent/NI200800020A/es unknown
- 2008-01-22 CR CR9678A patent/CR9678A/es unknown
- 2008-01-28 MA MA30609A patent/MA29652B1/fr unknown
- 2008-01-29 US US12/021,638 patent/US8058290B2/en active Active
- 2008-01-30 EC EC2008008152A patent/ECSP088152A/es unknown
- 2008-02-01 KR KR1020087002822A patent/KR101263970B1/ko not_active Expired - Fee Related
- 2008-02-04 HN HN2008000188A patent/HN2008000188A/es unknown
- 2008-02-26 NO NO20081013A patent/NO20081013L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070240A1 (es) | 7-aza-indazoles sutituidos, composiciones que los contienen y procedimiento de fabricacion | |
| NO942618D0 (no) | Imidazolderivater og deres anvendelse som cytokin-inhibitorer | |
| DK529888A (da) | Substituerede n-(1-alkyl-3-hydroxy-4-piperidinyl) benzamider | |
| MEP51408A (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
| PE20080205A1 (es) | DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2 | |
| PE20020381A1 (es) | COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA COMO INHIBIDORES DE LA PROTEINA QUINASA | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20071420A1 (es) | Pirrolopiridinas sustituidas, composiciones que las contienen y proceso de fabricacion | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| YU46195B (sh) | Postupak za dobijanje antiaritmičkih agenasa | |
| BRPI0406762A (pt) | Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça | |
| DE19775082I2 (de) | Indol-Derivate. | |
| AR035111A1 (es) | Procedimiento para preparar un compuesto de pirimidinona | |
| ATE422884T1 (de) | Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie | |
| DE69131759D1 (de) | An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one | |
| PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
| PE20061086A1 (es) | Pirroles sustituidos, composiciones que los contienen y proceso de fabricacion | |
| PE20020760A1 (es) | Derivados de pirimidina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| GB1109525A (en) | Cyano-acylated cephalosporin derivatives and process for their manufacture | |
| ATE40369T1 (de) | Purinderivate. | |
| SE8107520L (sv) | 7-acylaminocefalosporansyraderivat och forfarande for framstellning derav | |
| EA200101109A1 (ru) | Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана | |
| PE20060738A1 (es) | Formas cristalinas de espiro-hidantoina substituidas con piridilo y procesos para su produccion | |
| ES8203901A1 (es) | Un procedimiento para la preparacion de benzamidas. | |
| PT82847B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo 4-amino-2-(imidazolodina-2-ona-1-il)-pirimidina-5-carboxil-(n-(3-trifluormetil-fenil)-amidas) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |